1. Generics Bulletin
  2. >>Business
  3. >>Deals

Biocon Boosts Biosimilars In Australia With Sandoz Partnership

Five-Year Exclusive Marketing Deal Will Cover Indian Firm’s Trastuzumab And Bevacizumab

 
• By Dave Wallace

Biocon Biologics is seeking to bolster its biosimilars business in Australia, recently integrated after being acquired from former owner Viatris, through a deal that will see Sandoz market its Ogivri and Abevmy versions of trastuzumab and bevacizumab.

Australian flag with vial and syringe
Biocon and Sandoz have struck a biosimilars deal in Australia • Source: Shutterstock

Biocon Biologics and Sandoz have struck a marketing partnership in Australia that will see Sandoz commercialize Biocon’s Ogivri (trastuzumab) and Abevmy (bevacizumab) biosimilars.

The five-year deal will give Sandoz exclusive rights to promote, sell and distribute the trastuzumab and bevacizumab biosimilars – which Biocon said had local markets valued at AUD35m ($22.8m) and AUD45m respectively – in Australia

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.